CHMP Backs Expanded Indications for Uplizna in NMOSD, IgG4-RD and gMG

Why It Matters

The label expansion opens a sizable, high‑unmet‑need market for Amgen, potentially boosting revenues and strengthening its position against rival B‑cell therapies. It also provides clinicians with a proven, targeted option across three distinct autoimmune diseases, accelerating patient access to disease‑modifying treatment.

Key Takeaways

• CHMP recommends Uplizna for NMOSD, IgG4‑RD, gMG.
• Indication covers anti‑AQP4 seropositive NMOSD adults.
• Approved as add‑on therapy for antibody‑positive generalized MG.
• Targets IgG4‑related disease across multiple organ systems.
• European Commission decision pending; EMA to update label.

Pulse Analysis

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion on 11 December 2025 to broaden the marketing authorisation of inebilizumab, sold as Uplizna. By adding neuromyelitis optica spectrum disorder (NMOSD), immunoglobulin G4‑related disease (IgG4‑RD) and generalized myasthenia gravis (gMG) to its label, the drug moves from a niche indication for NMOSD into a multi‑indication platform targeting three distinct autoimmune disorders. Such regulatory expansions are rare in the EU, reflecting both the strength of the clinical data and the agency’s willingness to support therapies that address high‑unmet‑need, rare‑disease markets.

For clinicians, the new recommendations translate into concrete treatment options. In NMOSD, Uplizna will be available as monotherapy for anti‑aquaporin‑4 seropositive adults, offering a B‑cell depleting strategy that has shown relapse‑reduction in pivotal trials. In IgG4‑RD, the drug addresses a chronic fibro‑inflammatory condition that currently relies on off‑label steroids and rituximab, potentially improving organ‑preserving outcomes. In generalized myasthenia gravis, the label positions Uplizna as an add‑on to standard therapy for patients positive for anti‑acetylcholine‑receptor or anti‑MuSK antibodies, expanding the therapeutic armamentarium for a disease with limited oral options.

Amgen stands to gain a significant revenue uplift from the expanded label. The combined prevalence of NMOSD, IgG4‑RD and gMG in Europe is estimated at over 150,000 patients, a market that could generate several hundred million euros annually if uptake mirrors early‑adopter patterns seen with other B‑cell therapies. The pending European Commission decision will trigger label updates in all EU languages, paving the way for national reimbursement negotiations. Competitors such as Roche’s ocrelizumab and Pfizer’s eculizumab will now face a broader, multi‑indication challenger, intensifying the race for market share in autoimmune neurology and systemic disease.